Therapy development inspired by patients


In developing effective therapy for neuro-degenerative diseases, such as ALS and Alzheimer’s disease, we are also committed to raising awareness about these complex and fatal diseases.


Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease (MND) in the UK and Lou Gehrig’s disease in the US, is a fatal neurodegenerative disease. Very little is known about this rare disease that causes muscle weakness, severe disability and ultimately death.

About 400.000 people live with the diagnosis of ALS and have, due to the lack of effective medication available, between 3 and 5 years to live. As the disease progresses, patients lose hand and arm function experience difficulty walking, eating, speaking and even breathing; the latter of which is often the cause of death. Therefore, it is of utmost importance to research its causes and develop effective treatment.

In raising awareness about ALS, we continue the legacy of Treeway’s founders and strive to increase funding for our research and drug development in order to ensure that every patient will be able to continue leading an independent and fulfilled life, even with the diagnosis.

If you like to know more about the disease and Treeway’s research and drug development program for ALS, click here to get to our pipeline or go to for more extensive explanations.


Alzheimer’s disease is a neurodegenerative disease and brain disorder that slowly destroys and affects memory, behavior and thinking skills. Alzheimer’s disease is a type of progressive dementia; its symptoms gradually worsen over the years. In its early stages, memory loss is mild, but with late-stage Alzheimer’s, individuals lose the ability to hold a conversation and respond to their environment.

Typically, the onset of Alzheimer’s occurs in the later stages of life and has a devastating impact on the patient and his or her social environment. Unfortunately, very little is known about Alzheimer’s disease, and apart from Aduhelm, an antibody targeting amyloid-beta that is indicated to treat Alzheimer’s disease, which has recently been approved by the FDA exclusively for the United States, there is still no effective treatment available to patients.

By raising awareness about this disease, Treeway strives to accelerate research and drug development in order to make effective treatment available for every patient as soon as possible.

If you would like to know more about the disease and our research and drug development program for Alzheimer’s disease, click here to get to our pipeline or go to for more information.